| Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma (NCT04871607) | City of Hope Medical Center | 2021-11-02 |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation (NCT03602898) | Fred Hutchinson Cancer Center | 2021-06-01 |
| Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma (NCT04640779) | Mayo Clinic | 2021-02-08 |
| Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies (NCT04681105) | City of Hope Medical Center | 2020-11-18 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer (NCT03739606) | City of Hope Medical Center | 2020-10-20 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524) | OHSU Knight Cancer Institute | 2020-04-01 |
| Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (NCT03739619) | Emory University | 2018-11-26 |
| Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer (NCT03432741) | Mayo Clinic | 2018-03-27 |
| Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (NCT03418038) | Mayo Clinic | 2018-03-23 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) (NCT03213665) | National Cancer Institute (NCI) | 2017-11-13 |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma (NCT03096782) | M.D. Anderson Cancer Center | 2017-10-13 |
| Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation (NCT03246906) | Fred Hutchinson Cancer Center | 2017-09-11 |
| Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT03013933) | City of Hope Medical Center | 2017-05-03 |
| Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma (NCT03057795) | City of Hope Medical Center | 2017-04-03 |
| Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02960646) | M.D. Anderson Cancer Center | 2017-01-18 |
| Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant (NCT02869633) | Vanderbilt-Ingram Cancer Center | 2016-11-01 |
| Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant (NCT02861417) | M.D. Anderson Cancer Center | 2016-08-05 |
| Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT02744612) | City of Hope Medical Center | 2016-06-20 |
| Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (NCT02824029) | Barbara Ann Karmanos Cancer Institute | 2016-06-01 |
| Personalized NK Cell Therapy in CBT (NCT02727803) | M.D. Anderson Cancer Center | 2016-05-19 |
| Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT02254239) | Mayo Clinic | 2016-02-04 |
| Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis (NCT02593123) | Virginia Commonwealth University | 2015-11-04 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (NCT02304458) | National Cancer Institute (NCI) | 2015-03-30 |
| Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT02227199) | University of Washington | 2014-10-10 |
| Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies (NCT01921387) | Fred Hutchinson Cancer Center | 2013-10-09 |
| Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (NCT01897012) | National Cancer Institute (NCI) | 2013-07-17 |
| Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant (NCT01822509) | National Cancer Institute (NCI) | 2013-05-16 |
| NK Cells in Cord Blood Transplantation (NCT01619761) | M.D. Anderson Cancer Center | 2013-05-03 |
| Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma (NCT01703949) | University of Washington | 2013-03-20 |
| Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies (NCT01527045) | Fred Hutchinson Cancer Center | 2012-09-25 |
| Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma (NCT01393717) | City of Hope Medical Center | 2011-10-20 |
| Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant (NCT01251575) | Fred Hutchinson Cancer Center | 2010-12-01 |
| Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01028716) | Fred Hutchinson Cancer Center | 2010-05-19 |
| Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma (NCT00860171) | Fred Hutchinson Cancer Center | 2009-02-01 |
| Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant (NCT00068718) | Fred Hutchinson Cancer Center | 2003-05-01 |